 Antares Pharma Inc NASDAQ: ATRS divested Otrexup methotrexate injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc NASDAQ: ASRT for 44 million inclusive of Otrexup WIP and finished inventory. Under the asset purchase agreement terms, Antares will receive an initial payment of 18.0 million at closing plus two additional time-based payments totaling 26.0 million in 2022. 